IPOs and Secondaries

IPOs and Secondaries Articles

Leading survey software products provider SurveyMonkey entered the market with a bang on Wednesday.
Elastic, creator the Elastic Stack, expects to price 7 million shares for an initial public offering valued up to more than $233 million.
Clinical-stage biopharmaceutical company Kodiak Sciences expects to price 9 million shares for an initial public company valued up to more than $155 million.
Stock buybacks are among the reasons corporate earnings are so strong, Dell may have an initial public offering, and other important business headlines.
This month is on track to be the most successful September for IPOs since 2000. A total of 13 firms are on this week's calendar looking to raise more than $1 billion in new capital.
With the markets at all-time highs, it is prime season for initial public offerings and companies can get more bang for their buck. There were a couple major IPOs this week that lived up to the hype...
Upwork expects to price more than 12 million shares to effect an initial public offering valued up to more than $169 million.
Eli Lilly spin-off Elanco Animal Health made a strong entrance to the market on Thursday.
Eventbrite entered the market with a bang on Thursday, at a more than a 56% premium to the set share price.
Riley Exploration, an independent oil and gas producer in the Permian Basin, has filed for an IPO to raise $115 million. The company was formed in June of 2016 and currently produces more than 3,000...
Event management company Eventbrite now intends to price 10 million shares for an initial public offering valued up to more than $264 million.
Clinical-stage biopharmaceutical company Urovant Sciences intends to price 10 million shares for an initial public offering valued up to $184 million.
Five IPOs raised $1.33 billion last week. In the week ahead, eight companies are seeking a total of $3.26 billion in the IPO market. More new capital has been raised to date this year than in all of...
Principia Biopharma now intends to price more than 6 million shares for an initial public offering valued up to more than $122 million.
Clinical-stage immuno-oncology company Allogene Therapeutics has filed with the SEC in regards to its initial public offering.